帕博西利布
医学
富维斯特朗
内科学
肿瘤科
乳腺癌
人口
化疗
转移性乳腺癌
癌症
来曲唑
安慰剂
无进展生存期
中性粒细胞减少症
阿那曲唑
妇科
雌激素受体
三苯氧胺
病理
替代医学
环境卫生
作者
Hope S. Rugo,Seock‐Ah Im,Anil A. Joy,Yaroslav Shparyk,Janice Walshe,Bethany Sleckman,Sherene Loi,Kathy Puyana Theall,Sindy Kim,Xin Huang,Eustratios Bananis,Reshma Mahtani,Richard S. Finn,Véronique Dièras
出处
期刊:The Breast
[Elsevier]
日期:2022-12-01
卷期号:66: 324-331
被引量:1
标识
DOI:10.1016/j.breast.2022.11.005
摘要
Previous analyses from the PALOMA-2 and PALOMA-3 studies showed that palbociclib (PAL) plus endocrine therapy (ET) prolongs time to first subsequent chemotherapy (TTC) versus placebo (PBO) plus ET in the overall population of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative (HR+/HER2-) advanced breast cancer (ABC). Here, we evaluated TTC in relevant patient subgroups.These post hoc analyses evaluated TTC by subgroup using data from 2 randomized, phase 3 studies of women with HR+/HER2- ABC. In PALOMA-2, postmenopausal patients previously untreated for ABC were randomized 2:1 to receive PAL (125 mg/day, 3/1-week schedule) plus letrozole (LET; 2.5 mg/day; n = 444) or PBO plus LET (n = 222). In PALOMA-3, premenopausal or postmenopausal patients whose disease had progressed after prior ET were randomized 2:1 to receive PAL (125 mg/day, 3/1-week schedule) plus fulvestrant (FUL; 500 mg; n = 347) or PBO plus FUL (n = 174).First subsequent chemotherapy was received by 35.5% and 56.2% in PALOMA-2 and PALOMA-3 after progression on palbociclib plus ET or placebo plus ET. Across all subgroups analyzed, the median progression-free survival (PFS) was longer in the PAL plus ET arm than the PBO plus ET arm. TTC was longer with PAL plus ET versus PBO plus ET across the same patient subgroups in both studies.Across all subgroups, PAL plus ET versus PBO plus ET had longer median PFS and resulted in prolonged TTC in both the PALOMA-2 and PALOMA-3 studies. Pfizer Inc (NCT01740427, NCT01942135).
科研通智能强力驱动
Strongly Powered by AbleSci AI